Sonoma Bio Home
Press Releases
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022
November 10, 2022
Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer
September 7, 2022
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center
August 24, 2022
Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH
August 17, 2022
Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases
June 8, 2022
Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer
November 16, 2021
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
September 16, 2021
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases
August 4, 2021
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases
September 30, 2020
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
February 6, 2020
Home
Mission
Culture
Team
Science
Pipeline
Careers
News
Contact
HOME
Mission
Culture
Team
Science
Pipeline
Careers
Investors
News
Contact
